Identification of Breath Biomarkers in Head and Neck Squamous Cell Carcinoma
A Prospective Cohort Study to Determine Specific Volatile Organic Compounds Present in Breath Samples of Patients With Oral Cavity or Oropharyngeal Squamous Cell Carcinoma Using Gas Chromotography-mass Spectrometry
Sponsor: Princess Alexandra Hospital, Brisbane, Australia
Suspended
Awaiting funding to facilitate selected-ion flow-tube mass spectrometry (SIFT/MS)
Listed as NCT02156180, this observational or N/A phase trial focuses on Oral Cavity Squamous Cell Carcinoma and Oropharyngeal Squamous Cell Carcinoma and remains suspended. Sponsored by Princess Alexandra Hospital, Brisbane, Australia, it has been updated 6 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Suspended
-
Jul 2024 — Sep 2024 [monthly]
Suspended
-
Jan 2021 — Jul 2024 [monthly]
Suspended
-
Jun 2018 — Jan 2021 [monthly]
Suspended
-
Apr 2018 — Jun 2018 [monthly]
Suspended
Phase: NA → None
▶ Show 1 earlier version
-
Jan 2017 — Apr 2018 [monthly]
Suspended NA
First recorded
Apr 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Princess Alexandra Hospital, Brisbane, Australia
- Queensland Centre of Excellence for Head and Neck Cancer
- Queensland Health Forensic and Scientific Services
For direct contact, visit the study record on ClinicalTrials.gov .